Search the Newsreel

OPKO Health secures $125m financing backed by mazdutide royalties

OPKO Health Inc. has secured $125 million in senior secured notes through an expanded financing agreement with HealthCare Royalty, a business of KKR. This financing is backed by OPKO’s royalty interests from its mazdutide license agreement with Eli Lilly and Company, with notes maturing …

OPKO Issues $125M Notes While Keeping Future Mazdutide Royalties

OPKO Health (NASDAQ: OPK) has expanded its financing relationship with HealthCare Royalty by issuing an additional $125 million in senior secured notes, backed by royalty interests from its mazdutide license with Eli Lilly. These notes mature in 2044, and the agreement caps total payments …

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

OPKO Health has expanded its financing relationship with HealthCare Royalty (HCRx), a KKR business, by issuing an additional $125 million in senior secured notes. These notes are backed by OPKO's royalty interests from its mazdutide license agreement with Eli Lilly and Company, maturing in …

OPKO Health Inc (OPK) Earnings Forecast: Future EPS & Revenue Growth Estimates

Does OPKO Health’s Sharply Narrowed Q2 Loss Reset the Bull Case for OPKO Health (OPK)?

OPKO Health, Inc. (OPK) reported a significantly narrowed net loss of US$8.42 million in Q2 2026, alongside increased revenue of US$163.58 million, which could signal progress in cost control and operations management. While the company remains unprofitable, this positive development, combined with their 2026 …

Opko Health | SCHEDULE 13D: Others

This article provides details about a Schedule 13D filing related to Opko Health. Schedule 13D filings are required when a person or group acquires more than 5% of a company's stock, indicating a potentially active investment or influence on the company.

OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know

OPKO Health: Mazdutide And MDX-2201 Could Change Everything (NASDAQ:OPK)

Cocrystal Pharma Secures $5 Million Investment from OPKO Health as Norovirus Program Advances Toward Phase 1b Data

Cocrystal Pharma has secured a $5 million investment from longtime investor OPKO Health, increasing OPKO's stake in the company. This funding will support Cocrystal's norovirus program, particularly its lead candidate CDI-988, as it advances towards releasing topline data from its Phase 1b clinical trial …

Cocrystal Pharma (NASDAQ: COCP) secures $5M investment from OPKO Health

Cocrystal Pharma has secured a $5 million investment from longtime investor OPKO Health through a private placement of 5,474,053 common shares at $0.9134 per share. The biotech company plans to use these proceeds to advance its preclinical and clinical antiviral programs, including its lead …

OPKO Buys 5.47M Cocrystal Shares Ahead of Late-2026 Norovirus Data

OPKO Health has made a $5 million private placement in Cocrystal Pharma, purchasing 5,474,053 common shares at $0.9134 per share. This investment aims to support the advancement of Cocrystal's lead norovirus candidate, CDI-988, with topline Phase 1b data anticipated by the end of the …

OPKO Health (OPK) Is Up 14.1% After Narrower Q2 Loss and New 2026 Revenue Guidance – Has The Bull Case Changed?

OPKO Health (OPK) reported a significantly narrower Q2 net loss of US$8.42 million and issued new 2026 revenue guidance of US$560 million to US$585 million, leading to a 14.1% stock increase. The article explores whether this reduced loss and updated guidance change the investment …

OPKO Health: A Hold As Progress Continues (NASDAQ:OPK)

Opko Health, Inc. Revenue Breakdown – NASDAQ:OPK

Opko Health, Inc. (NASDAQ: OPK) generated $606.90 million in revenue last year, with its Diagnostics segment being the top performer at $370.27 million. The United States was the largest geographical contributor, accounting for $436.06 million of the revenue. These figures provide a breakdown of …

Earnings Beat: OPKO Health, Inc. (NASDAQ:OPK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

OPKO Health, Inc. recently reported a significant earnings beat, surpassing analyst revenue and statutory EPS forecasts. Following these results, analysts have raised their revenue and EPS estimates for the company's future performance, suggesting a more optimistic outlook. The revised forecasts indicate a positive sentiment …

OPKO Health FY2026 EPS Estimate Increased by HC Wainwright

HC Wainwright has increased its FY2026 EPS estimate for OPKO Health to a loss of $0.23 per share from $0.30, while maintaining a "Buy" rating. This upgrade follows OPKO's recent quarterly results, which surpassed expectations with a $0.01-per-share loss against an estimated $0.08 loss …

Is OPKO Health (OPK) A Bargain After Its Q2 Earnings And 52 Week High?

OPKO Health Number of Employees 2026 | Employee Count & Headcount Data

OPKO Health (NASDAQ: OPK) had approximately 2,275 employees worldwide as of March 2026, representing a 13.9% decline from 2023. Despite this decline, the company is actively hiring, with 129 active job postings in 2026, a 71.6% increase from the previous year. The workforce is …

OPKO Health (NASDAQ:OPK) Reaches New 52-Week High - Here's Why

OPKO Health (NASDAQ:OPK) shares recently hit a new 52-week high after reporting second-quarter results that significantly beat expectations. The company narrowed its adjusted loss and saw revenue rise 4.3% year over year, leading management to raise its 2026 revenue outlook. Despite these positive developments …

OPKO Health gives back 17% after sharp post-earnings surge (OPK:NASDAQ)

OPK|OPKO Health Inc|Price:1.650|Chg%:+0.410

This article provides a comprehensive stock analysis of OPKO Health Inc (OPK), highlighting its healthy fundamentals, significant growth potential, and fair valuation within the Healthcare Providers & Services industry. It notes high institutional ownership and recent "Buy" ratings from analysts, with expectations for the …

OPKO Health (OPK) VP withholds 53,266 shares for taxes

OPKO Health's Executive VP-Administration, Steven D. Rubin, reported a tax-related share withholding on July 24, 2026. A total of 53,266 shares of common stock, valued at $1.22 per share, were withheld to cover tax obligations stemming from vested restricted stock units. Following this transaction, …

OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates

OPKO Health reported a narrower-than-expected loss and higher revenues for Q2 2026, driven by strong growth in its Pharmaceuticals segment and exceeding analyst estimates. The company also raised its full-year 2026 revenue guidance. This positive performance is attributed to improved pharmaceutical revenues, including income …

Biopharmaceutical and Diagnostics Stock OPKO Health, Inc. (NASDAQ: OPK) Reaches 52 Week High on Second Quarter News

OPKO Health, Inc. (NASDAQ: OPK) saw its stock reach a new 52-week high after reporting strong second-quarter 2026 financial results and significant progress in its clinical programs. The company posted consolidated revenue of $163.5 million and a narrowed net loss of $8.4 million, with …

OPKO Health Q2 Earnings Call Highlights

OPKO Health reported a narrower Q2 loss and increased revenue, driven by diagnostics restructuring and a China commercialization agreement. The company ended the quarter with over $300 million in cash and repurchased 9.7 million shares. OPKO also raised its full-year revenue outlook and continues …

OPKO Health (NASDAQ:OPK) Shares Gap Up Following Strong Earnings

OPKO Health (NASDAQ:OPK) saw its shares gap up after reporting better-than-expected quarterly earnings, with a loss of $0.01 per share against an anticipated $0.08 loss and revenue of $163.58 million, exceeding estimates. The company also raised its 2026 revenue outlook and plans to advance …

OPKO Health (OPK) Stock Jumps As Losses Shrink And Pipeline Progress Builds

OPK Looks 17.0% Overvalued on GF Value™

OPKO Health Inc (OPK) is currently valued as 17.0% overvalued based on GuruFocus's GF Value™ at $1.24 per share against an intrinsic value of $1.06, despite beating Q2 revenue expectations. The company, operating in medical diagnostics and research, shows mixed signals with a GF …

OPKO Health Inc reports results for the quarter ended June 30 - Earnings Summary

OPKO Health Inc has released its financial results for the quarter ended June 30. The article, sourced from Reuters, provides an earnings summary for the company. Readers can access the full report on TradingView.

OPKO HEALTH ($OPK) Releases Q2 2026 Earnings, Stock Rises

OPKO Health: Q2 Earnings Snapshot

This article is an earnings snapshot for OPKO Health's Q2 results. However, the content provided is incomplete and does not contain any financial details or specific information regarding their performance.

OPKO Begins Phase 1 Trials in B-Cell Lymphoma, COVID Prevention

OPKO Health reported Q2 2026 revenues of $163.5 million, an increase from the previous year, with a narrowed net loss. The company highlighted significant progress in its clinical programs, including initiating Phase 1 trials for MDX2003 in B-cell lymphoma and MDX2301 for COVID-19 prevention, …

OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results

OPKO Health, Inc. reported its second-quarter 2026 financial results, showcasing significant progress in its clinical pipeline, particularly with ModeX and OPKO Biologics. The company saw an increase in total consolidated revenues to $163.5 million, up from $156.8 million in 2025, and a reduced net …